OH Pharma
Products › Metabolism › Tirzepatide 10 mg
Tirzepatide 10 mg OH PharmaTirzepatide 10 mg OH Pharma – back of vial

Metabolism · File 20

Tirzepatide 10 mg

Certificate of analysis available

✓Sterility and endotoxins tested by Nelson Labs (Salt Lake City)

Purity (HPLC)99.5 %
LotGN2605
LaboratoryBTLabs
Calculate a dose →

Description

Dual agonist of the GIP and GLP‑1 receptors, two gut hormones involved in regulating appetite and blood sugar.

Studied benefits

  • Reduced appetite, increased satiety and substantial weight loss.
  • Improved blood sugar in type 2 diabetes.
  • Reduced severity of obstructive sleep apnea in adults with obesity.
  • In patients with obesity and heart failure with preserved ejection fraction: improved symptoms and physical capacity, and fewer heart-failure exacerbations.
  • Encouraging results on MASH resolution in a phase 2 trial.

Results reported in published research; they guarantee no effect and are not an indication for use.

🔬 What the research says
  • SURMOUNT‑1 trial (NEJM, 2022; 2,539 adults, 72 weeks): mean weight loss of up to 20.9% at 15 mg weekly, versus 3.1% on placebo.
  • Used by prescription for type 2 diabetes and weight management.
⚠️ Warnings and reported side effects
  • Common digestive effects: nausea, diarrhea, constipation, vomiting, especially when the dose is increased.
  • GLP‑1 class warnings: pancreatitis, gallbladder disorders, thyroid tumours seen in rodents; contraindicated with a history of medullary thyroid cancer.
  • Risk of hypoglycemia if combined with insulin or certain diabetes medications. Not recommended during pregnancy.

Consult a healthcare professional before any use. If an adverse effect occurs, stop use and see a doctor.

Certificate details

Laboratory
BTLabs (West Palm Beach, FL, United States)
Report number
IF-824-QSA-TR006-BTL26632-02
Substance analyzed
Tirzepatide
Lot
GN2605
Analysis date
June 1, 2026
Report date
June 5, 2026
Labelled sample content
10 mg
Sample ID
005000040271678

Results

TestMethodSpecificationResult
Identity and composition (FTIR)USP <197A>Confirms the presence of the peptideConfirmedPass
Purity (HPLC)USP <621>≥ 98 %99.5 %Pass
Measured content (HPLC)USP <621>90 – 110 % de 10 mg10 mg (100.3 %)Pass
Total massUSP <41>As measured105.5 mg

According to the laboratory, this analysis covers identity, purity, content and composition. It does not cover particulates, microbial contamination or endotoxins. Sterility and endotoxins are tested separately by Nelson Labs (Salt Lake City, Utah).

How to read this certificate →

Original certificate

Certificate of analysis Tirzepatide 10 mg, page 1Certificate of analysis Tirzepatide 10 mg, page 2 Download the certificate (PDF)

Sources

  1. Jastreboff et al., NEJM 2022 — SURMOUNT‑1 trial

For educational purposes only. This information summarizes published studies and is neither a recommendation for use nor medical advice.

← Back to products